

Active substances set

Search phrase: datopotamab deruxtecan

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Malignant breast cancer

Datopotamab deruxtecan

Breast cancer Datopotamab deruxtecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one line of chemotherapy in the advanced setting.



NO REIMBURSEMENT



ESMO